Journal article icon

Journal article

Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.

Abstract:

INTRODUCTION: The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. Disease incidence is low in healthy 6 - 17-year-old children and young people; however, there are a number of clinical conditions that put individuals in this age group at increased risk. Expansion of the license of a 13-valent pneumococcal conjugate vaccine , PCV-13, to include the 6 - 17 age group has...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Mitchell, R More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Paediatrics, Biomedical Research Centre
Journal:
Expert opinion on biological therapy
Volume:
13
Issue:
10
Pages:
1451-1465
Publication date:
2013-10-05
DOI:
EISSN:
1744-7682
ISSN:
1471-2598
URN:
uuid:50164cbc-5411-4b3e-a0fa-61c48e3d0ff0
Source identifiers:
416701
Local pid:
pubs:416701

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP